Get started
Arrowhead Pharmaceuticals, Inc.Arrowhead Pharmaceuticals, Inc.Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

ARWR trade ideas

Arrowhead Pharmaceuticals Massive Institutional AccumulationStock tanked last year because hep b trials killed a chimp, so they shelved project to focus on Amgen and RNAi program therapies. Buy half now, buy the other half on a pullback. Fucking beautiful chart. BEAUTIFUL Only short to medium term risk is dilution, which is a very real possibility . The buying is just SO strong though, wow. BEAUTIFUL, like, it's ....just,.....its a beautiful chart. So firm and consistent, and green, with heavy volume. For it to have responded so strongly after a major investor left is very indicative of positive outcomes in the future. Late 2016 -Amgen to Receive Worldwide Exclusive License to Arrowhead's RNAi ARC-LPA Program -Amgen Receives Exclusive License Option to RNAi Therapy for Undisclosed Cardiovascular Target -Arrowhead to Receive $56.5 Million in Upfront Payments and Initial Equity Investment and up to an Additional $617 Million in ------Potential Milestone and Equity Payments up to $617 million in option payments, and development, regulatory and sales milestone payments "Arrowhead's expertise in RNAi makes them a valuable partner as we translate genetic discoveries into potential therapies that can improve health outcomes for patients," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "This collaboration builds upon our commitment to cardiovascular disease with targets that we believe are uniquely suited for RNAi-based therapy." "We have made great advances to our proprietary subcutaneous RNAi delivery vehicle and in RNAi trigger modification and stabilization that enable rapid development of new RNAi therapeutics across multiple disease areas," said Christopher Anzalone, Ph.D., president and chief executive officer at Arrowhead. "Our capabilities and platform technologies are becoming increasingly validated, so we feel that now is a great time to expand the reach of our technologies and partner with other companies to maximize the value of our assets. We are thrilled to be working with Amgen, one of the world's leading biotechnology companies, on this collaboration. Amgen's extensive development, regulatory, and commercial expertise makes them an ideal partner, and we look forward to a long and productive relationship."
NASDAQ:ARWRLong
by alipipefitter
ARWR Bearish Reversal NASDAQ:ARWR just reached a previous top and has gone down 3 days in a row. Selling pressure is increasing. It just broke a trend line that was consistent for 21 days. Price Oscillator and RSI both broke significant trendlines on 3/6. MACD just had a negative crossover indicating a sell signal. CMF is downtrending and the Parabolic SAR is close to negatively crossing over. Trendline violations for the Price Oscillator confirm on the 14 day chart, 25 day chart, and 45 day chart. On the 65 day chart it looks like it reached a peak and is downsloping but hasnt confirmed yet. RSI trendline violations confirm on 14,25,45, and 65 day charts.
NASDAQ:ARWR
by ARYK0
ARWR next few days will determine uptrend or downtrend NASDAQ:ARWR The next couple of days will determine a short term potentially sharp uptrend or downtrend. RSI just crossed through a trendline and if price confirms and breaks trend, it could see a sharp downtrend. My MACD sell trigger is converging negatively which means a sell signal could come soon. CMF has been in a small price range the past 3 days that could be a sign that price is ready to make a move. It also has a gap to cover from 2.47 - 4.35. It just broke above 200 day MA.
NASDAQ:ARWR
by ARYK0
1
Diamond Bullish Bottom (Time to get long or Wait?)Buyers were unable to keep their control though they have shown enough force last few weeks. Now it looks we have printed the bottom and ready to reverse upside from recent consolidation period or tight range. July's low $10.62 come after price fell from June high 15.73 with very light volume, and price kicked in upside with heavy volume which suggest institutions were buying and actually their ownership increased since July low. The Diamond Bottom pattern begins during a downtrend as prices create higher highs and lower lows in a broadening pattern. Then the trading range gradually narrows after the highs peak and the lows start trending upward. When the price breaks upward out of the diamonds boundary lines, it marks a significant reversal to a new uptrend. Target price: $19.50-$20 make your stop loss at recent swing low at $12.17. If you want to have a real time alerts check www.2waytrading.com
NASDAQ:ARWRLong
by Xafada